Published in Obesity and Diabetes Week, October 10th, 2005
According to a study from Nigeria and the United States, "There are scant data from African populations on the association between beta-cell function and response to treatment with oral hypoglycemic agents in type 2 diabetes mellitus (T2DM). Fasting plasma C-peptide (FCP) and glucagon-stimulated C-peptide (GSCP) levels were measured in 116 Nigerians with T2DM at a university teaching hospital."
"After nine months of follow-up and treatment, they were categorized into three groups...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.